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 Diabetes mellitus is the most prevalent endocrine dis-
ease in developed countries [1], and diabetic retinopathy is
the leading cause of blindness in the world [2,3]. Blood-reti-
nal barrier (BRB) breakdown, increased vascular permeabil-
ity and vascular leakage are early complications of diabetes
and a major cause of diabetic macular edema [4-6]. As there is
no satisfactory or noninvasive therapy, diabetic macular edema
is a major cause of vision loss in diabetic patients [7].
An ideal treatment strategy would be to deliver a thera-
peutic gene with a vector that could confer long-term transgene
expression and tissue protection with a single administration.
We have previously reported that a recombinant adeno-asso-
ciated virus vector expressing angiostatin (rAAV-angiostatin)
suppressed laser-induced choroidal neovascularization [8].
Recently, an effect of angiostatin in reducing vascular perme-
ability in the retina in diabetic and oxygen-induced retinopa-
thy models was reported [9].
Angiostatin (Kringles 1 through 4) is a proteolytic frag-
ment of plasminogen [10]. It was identified as a potent angio-
genic inhibitor, which blocks neovascularization and sup-
presses tumor growth and metastases [10,11]. Angiostatin spe-
cifically inhibits proliferation, induces apoptosis in vascular
endothelial cells [12], and downregulates vascular endothe-
lial growth factor (VEGF), the latter via inactivation of the
p42/p44 MAP kinase pathway [9,13,14]. We also noted that
some proteolytic fragments of plasminogen can induce
upregulation of pigment epithelium-derived factor (PEDF)
expression, a potent angiogenic inhibitor in experimental dia-
betes [15].
BRB breakdown may be due to disassembly of unique
proteins that constitute the functional vascular endothelial tight
junction [16-18]. VEGF is a potent angiogenic factor [13],
whose overproduction in the retina has been noted in the de-
velopment of vascular hyperpermeability in diabetes [14].
Furthermore, VEGF affects the tight junction protein occludin,
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Purpose: To evaluate the efficacy of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin
(Kringle domains 1 to 4) in reducing retinal vascular leakage in an experimental diabetic rat model.
Methods: rAAV-angiostatin was delivered by intravitreal injection to the right eyes of Sprague-Dawley rats. As a control,
the contralateral eye received an intravitreal injection of rAAV-lacZ. Gene delivery was confirmed by reverse-transcriptase
polymerase chain reaction (RT-PCR). Diabetes was induced by intravenous injection of streptozotocin (STZ). Vascular
permeability changes were evaluated by extravascular albumin accumulation and leakage of intravenous-injected fluores-
cein isothiocynate-bovine serum albumin (FITC-BSA). Effects of rAAV-angiostatin on expression of vascular endothelial
growth factor (VEGF), pigment epithelium-derived factor (PEDF), occludin, and phospho-p42/p44 MAP kinase in retina
tissue were analyzed by western blotting.
Results: The rAAV-angiostatin injections led to sustained angiostatin gene expression in retina as confirmed by RT-PCR,
and reduced extravascular albumin accumulation in STZ-induced diabetic retina. Further, rAAV-angiostatin significantly
decreased intravascularly injected FITC-BSA leakage at 5 days (p=0.001), 10 days (p<0.001), and 15 days (p=0.001) after
STZ-induced diabetes, as compared to the control eyes receiving rAAV-lacZ. Expression of VEGF and phosphorylation
of p42/p44 MAP kinase in retina was reduced by rAAV-angiostatin at day 1 (p=0.043 for both VEGF and phospho-p42/
p44 MAP kinase) after STZ-induced diabetes compared with rAAV-lacZ eyes. rAAV-angiostatin reduced retinal occludin
loss at 10 days after STZ-induced diabetes (n=5, p=0.041). There was no significant difference in retinal PEDF expression
between eyes injected with rAAV-angiostatin and rAAV-lacZ.
Conclusions: Intravitreal delivery of rAAV-angiostatin reduces vascular leakage in an STZ-induced diabetic model. This
effect is associated with a reduction in the retinal occludin loss induced by diabetes and downregulation of retinal VEGF
and phosphor-p42/p44 MAP kinase expression. This gene transfer approach may reduce diabetic macular edema, provid-
ing protection in diabetic patients at risk for macular edema.
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133inducing occludin phosphorylation [19] and redistribution [20];
resultant occludin reduction is associated with BRB break-
down in diabetes [21].
The present study was designed to examine the transgenic
expression of rAAV-angiostatin in the eye and its effect on
vascular permeability in the streptozotocin (STZ)-induced dia-
betic model. Since it has been demonstrated angiostatin can
induce the downregulation of VEGF through the blockade of
phosphorylation of p42/p44 MAP kinase [9,13,14], we also
studied the relationship between rAAV-angiostatin, p42/p44
MAP kinase, occludin, VEGF, and PEDF in this model.
METHODS
Animals:  Male Sprague-Dawley (SD) rats (Charles River
Laboratories, WilmingtonMA) weighing approximately 200
g on arrival were used in this study. The animals were cared
for in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. All experimen-
tal procedures used aseptic sterile techniques and were ap-
proved by the Animal Care and Use Committee of the Mackay
Memorial Hospital.
Generation of rAAV-angiostatin:  cDNA coding for
angiostatin was amplified by polymerase chain reaction (PCR)
according to a published report [22]. rAAV encoding mouse
angiostatin cDNA or lacZ were constructed by using a three-
plasmid cotransfection system as described previously [22-
24]. Titers of rAAV-angiostatin and rAAV-lacZ were deter-
mined by dot blot hybridization using angiostatin cDNA and
lacZ as probes [25].
Intravitreal injections of rAAV-angiostatin:  After being
anesthetized, each animal received an intravitreal injection of
rAAV- angiostatin (5 µl, 1.5x1010 viral particles) as described
previously [26]. The contralateral eye of each rat was injected
with rAAV-lacZ to serve as a control.
Experimental Diabetes:  Experimental diabetes was in-
duced three weeks after intravitreal injection of rAAV. Diabe-
tes was induced with a single 60 mg/kg intravenous injection
of streptozotocin (Sigma-Aldrich, St. Louis, MO) in 10 mM
citrate buffer, pH 4.5. Animals that served as nondiabetic con-
trols received an equivalent amount of citrate buffer alone [21]
Twenty-four h later, rats with blood glucose levels higher than
250 mg/dl were deemed diabetic. These diabetic rats received
6-8U NPH insulin (Lilly, Indianapolis, IN) once a week to
prevent ketoacidosis. Just before experimentation, blood glu-
cose levels were measured again to confirm diabetic status.
Reverse transcription-polymerase chain reaction:  Ex-
pression of rAAV-angiostatin in retina was confirmed by RT-
PCR according to a protocol described in reference [8]. Each
rat eye that was previously injected with rAAV-angiostatin and
rAAV-lacZ was enucleated, and chorioretinal tissues were
harvested for RT-PCR at 1, 5, 10, and 15 days after induction
of experimental diabetes. The cDNA was synthesized using
oligo(dT) primer and 200 IU transcriptase (SuperScript II; Life
Technologies, Carlsbad, CA) according to the manufacturer’s
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TABLE 1. ANIMAL PHYSIOLOGICAL VARIABLES
                                                    After streptozotocin induction of diabetes
                              ---------------------------------------------------------------------------------------
            Baseline (n=4)           5 Days (n=4)                  10 Days (n=4)                 15 Days (n=4)
           ----------------   ---------------------------   ---------------------------   ---------------------------
                                       Increase                      Increase                      Increase
                     Blood             in body     Blood             in body     Blood             in body     Blood
                     sugar              weight     sugar              weight     sugar              weight     sugar
 Sample    BW (g)   (mg/dl)   BW (g)     (%)      (mg/dl)   BW (g)     (%)      (mg/dl)   BW (g)     (%)      (mg/dl)








rat        251+11   143+ 9    257+10     2.4      352+15    270+14      7.7     377+13    280+11     11.6     396+15
Animals were made diabetic by a single streptozocin (STZ) injection (65 mg/kg) in 1 mmol/l sodium citrate buffer, pH 4.5. All diabetic
animals had higher blood glucose levels and reduced body weight gain compared to age matched, non-diabetic control animals.
Figure 1. RT-PCR analysis of angiostatin cDNA in chorioretinal tis-
sue.  The eyes previously injected with rAAV-lacZ (lanes B to E) and
rAAV-angiostatin (lanes F to I) were enucleated and chorioretinal
tissues were harvested for RT-PCR at 1, 5, 10, and 15 days after
induction of experimental diabetes. Lane A is the control eye. Lanes
B and F are 1 day after diabetes induction. Lanes C and G are 5 days
after diabetes induction. Lanes D and H are 10 days after diabetes
induction. Lanes E and I are 15 days after diabetes induction. There
was no angiostatin gene expression in the control eye (lane A) and
eyes injected with rAAV-lacZ (lanes B to E). In the eyes injected
with rAAV-angiostatin, angiostatin gene expression was detected
(lanes F to I). As an internal control, expression of GAPDH was
detected in normal control eye and eyes receiving both rAAV-
angiostatin and rAAV-lacZ injections (lanes A to I). “M” indicates
molecular weight markers.
134instructions. PCR amplification was performed with two oli-
gonucleotide primers, 5'-CAG CAA TGC GTG ATC ATG-3'
and 5'-TGG AGA TTT TGC CCT CAT AC-3'. As a control,
PCR amplification was performed for glyceradehyde-3-phos-
phate dehydrogenase (GAPDH) with two oligonucleotide
primers, 5'-GGA AGG GCT CAT GAC CAC AG-3' and 5'-
CCT TTA GTG GGC CCT CGG-3'. To rule out the possibil-
ity that gene amplification products were derived from ampli-
fication of contaminating angiostatin genomic DNA, we treated
the total RNA with RNase free DNase I (Qiagen, Valencia,
CA) before RT-PCR.
Immunofluorescence assay:  Five-µm-thick retinal tissue
sections from formalin-fixed, paraffin-embedded blocks were
transferred to positively charged slides to be used for staining.
Sections were dewaxed in xylene and progressively hydrated
[27]. They were then washed three times with PBS and a 1:400
dilution of polyclonal rabbit antihuman albumin antibody
(DAKO Diagnostics. Mississauga, ON, Canada) was applied.
A fluorescein isothiocyanate (FITC)-conjugated antimouse IgG
was used as a secondary antibody. The results were viewed
with a fluorescence microscope (Zeiss Axioplan HBO100,
Oberkochen, Germany).
Measurement of leakage with intravascular injected FITC-
BSA:  Retinal vascular leakage was measured using the intra-
vascular injected FITC-BSA as previously described [21,28]
with some modifications. After induction of anesthesia, the
rats received tail vein injections of 100 mg/kg FITC-bovine
serum albumin (FITC-BSA, Sigma-Aldrich). The animals were
sacrificed 20 min later, and their eyes were removed, embed-
ded in OCT medium, and snap-frozen in liquid nitrogen. The
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Figure 2. Representative retinal sections following immunostaining for albumin.  Increased immunostaining was present throughout the retina
one week after STZ-induction of diabetes in eyes receiving rAAV-lacZ injection (B) compared to the normal Sprague-Dawley rat (A) where
staining was restircted to blood vessels. C: Intravitreal injection of rAAV-angiostatin decreased immunostaining in the retina one week after
induction of diabetes. Magnification X200. IPL denotes the inner plexiform layer, INL indicates the inner nuclear layer, and ONL marks the
outer nuclear layer.
Figure 3. FITC-BSA fluorescence in normal and streptozotocin (STZ)-induced diabetic rat retina.  A: Hematoxylin and eosin staining of
control retina. B: FITC-BSA fluorescence is limited to the vasculature in the normal retina and in C is diffusely increased throughout the
retinal parenchyma at 5 days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection. Increased fluorescence intensity throughout
the retinal parenchyma is still present at 10 (D) and 15 (E) days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection. F: Little
fluorescence was present in the retinal parenchyma in eyes receiving rAAV-angiostatin injection at 5 days after induction of diabetes. Retinal
parenchyma fluorescence at 10 (G) and 15 (H) days after induction of diabetes in eyes with rAAV-angiostatin injection was decreased as
compared with eyes with rAAV-lacZ injection. Original magnification was 200X.
135plasma was collected and assayed for fluorescence with an
SPEX fluorescence spectrophotometer (Molecular Devices,
Sunnyvale, CA) based on standard curves of FITC-BSA in
normal rat plasma. Frozen retinal sections (6 µm thick) col-
lected every 60 µm were viewed with a Zeiss Axioplan
HBO100 fluorescence microscope. Images from six retinal
nonvascular areas (200 µm2) in each section were collected.
Quantification of FITC-BSA fluorescence intensity was cal-
culated by computer software Q-win (Leica, Wetzlar, Ger-
many) and normalized to plasma fluorescence intensity for
each animal.
Western blot analysis of VEGF, PEDF, occludin, and p42/
p44 MAP kinase:  Rats were sacrificed, and their eyes were
removed for western blotting analysis at 1, 5, 10, and 15 days
after STZ treatment. The chorioretinal tissue was harvested,
and the soluble fractions were prepared by homogenizing the
retina in Eppendorf tubes containing RIPA lysis buffer (50
mM Tris, 150 mM NaCl, 10 mM EDTA, 0.1% SDS, 1% NP-
40, 0.5% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1
mM EGTA, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml
pepstatin A). Proteins (50 µg) were extracted for electrophore-
sis on 10% SDS-polyacrylamide gels. The membranes were
incubated with antibody specific to VEGF [29,30], PEDF [31],
p42/p44 MAP kinase [21] (all from Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA) and occludin [20] (Zymed, San
Francisco, CA). The results were semiquantified by densito-
metry (Fujifilm LAS3000, Tokyo, Japan) and normalized to
actin levels.
Cell culture and rAAV-angiostatin infection:  To further
evaluate whether angiostatin could induce the expression of
PEDF in endothelial cells, we infected human umbilical vein
endothelial cells (HUVEC-2C, Cascade Biologics, Portland,
OR) with rAAV-angiostatin. The HUVEC-2C cells were cul-
tured in medium 200 (Cascade Biologics) containing low se-
rum growth supplement. All cells were supplemented with 1%
penicillin-streptomycin and maintained at 37 °C and 5% CO2.
Confluent cells obtained during the fifth passage were used
for rAAV-angiostatin infection. The HUVEC-2C cells were
infected by rAAV-angiostatin in Dulbeco’s modified Eagle’s
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Figure 4. Quantification of vascular leakage in experimental diabe-
tes.  FITC-BSA fluorescence intensity was measured by image analy-
sis in serial retinal sections. Rats each received an intravenous injec-
tion of FITC-BSA were sacrificed at 5, 10, and 15 days after induc-
tion of diabetes. The average retinal FITC-BSA fluorescence inten-
sity was calculated and normalized to plasma fluorescence intensity.
The retinal FITC-BSA fluorescence intensity in eyes receiving rAAV-
angiostatin injection was 2.99±0.62 pixels at 5 days, 3.42±0.38 pix-
els at 10 days and 3.30±0.40 pixels at 15 days after induction of
diabetes. The retinal FITC-BSA fluorescence intensity in eyes re-
ceiving rAAV-lacZ injection was 3.59±0.31 pixels at 5 days, 3.77±0.51
pixels at 10 days and 3.71±0.47 pixels at 15 days after induction of
diabetes. The normalized FITC-BSA fluorescence intensity in eyes
receiving rAAV-angiostatin was decreased as compared to eyes re-
ceiving rAAV-lacZ at 5 days (t=3.67, n=49, p=0.001), 10 days (t=3.94,
n=51, p<0.001), and 15 days (t=3.52, n=56, p=0.001) after STZ-in-
duction of diabetes. The asterisk indicates a p less than or equal to
0.001. Four SD rats were represented by the number of sections (n)
to be examined.
Figure 5. The effect of rAAV-angiostatin gene transfer on retinal
occludin expression 10 days after STZ-induction of diabetes.  The
rats received intravitreal injection of rAAV-angiostatin in the right
eyes and rAAV-lacZ in left eyes, and diabetes was induced three weeks
after injection. A: Each blot is a representative of the results from
five rats. B: Occludin levels were semi-quantified by densitometry,
and normalized to actin. The rAAV-angiostatin significantly decreased
retinal occludin loss as compared to eyes receiving rAAV-lacZ injec-
tion at 10 days after induction of diabetes (the asterisk indicates sig-
nificance using the Wilcoxon signed rank test, n=5, p=0.041).
136medium for two days. Cell lysates were then prepared and
analyzed for PEDF by western blotting as described in the
previous paragraph.
Statistical Analyses:  The results are expressed as the
mean±SD. Retinal FITC-BSA fluorescence intensity was ana-
lyzed in serial retinal sections from four rats at 5, 10, and 15
days after induction of diabetes. Due to skewed distributions,
data were subjected to logarithmic transformation for analy-
sis. Differences of retinal FITC-BSA fluorescence intensity
between eyes receiving rAAV-angiostatin and rAAV-lacZ in-
jection at 5, 10, and 15 days after induction of diabetes were
analyzed by a paired-sample Student’s t test. The retinal ex-
pression of VEGF, PEDF, phosporylation of p42/p44 MAPK,
and occludin were analyzed by the Wilcoxon signed-rank test.
All p-values are two-tailed, and differences were considered
to be statistically significant for p<0.05.
RESULTS
Gene delivery by rAAV-angiostatin:  There was no angiostatin
gene expression in normal control eyes (Figure 1, lane A) and
eyes injected with rAAV-lacZ at 1, 5, 10, and 15 days after
induction of diabetes (Figure 1, lanes B-E). In the eyes in-
jected with rAAV-angiostatin, angiostatin gene expression was
detected at 1, 5, 10, and 15 days after induction of diabetes
(Figure 1, lanes F-I). As an internal control, expression of
GAPDH was detected in normal control eye and eyes receiv-
ing both rAAV-angiostatin and rAAV-lacZ injections (Figure
1, lanes A-I).
Induction of experimental diabetes:  Animals (n=12) with
a blood glucose exceeding 250 mg/dl were selected for inclu-
sion in the diabetic group. All diabetic animals had higher blood
glucose levels and reduced body weight gain at 5, 10, and 15
days after induction of diabetes compared to age-matched,
nondiabetic control animals (Table 1).
rAAV-angiostatin influence on vascular permeability:
One week after induction of diabetes, the immunofluorescence
assay, using anti-albumin antibody, disclosed staining only in-
side blood vessels in normal control eyes (Figure 2A). In-
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Figure 6. The effect of rAAV-angiostatin gene transfer on retinal
VEGF expression at 1 day after STZ-induction of diabetes.  A: The
blots show representative of results from six rats. B: VEGF levels
were semiquantified by densitometry and normalized by actin lev-
els. rAAV-angiostatin decreased the expression of VEGF as com-
pared to eyes with rAAV-lacZ injection (the asterisk indicates sig-
nificance using the Wilcoxon signed rank test, n=6, p=0.043).
Figure 7. The effect of rAAV-angiostatin gene transfer on retinal PEDF
expression.  A: There was no apparent difference in retinal PEDF
expression between eyes exposed to rAAV-angiostatin and rAAV-
lacZ. at 1, 5, 10, or 15 days after STZ injection. B: There was no
increase in PEDF expression in HUVEC-2C cells receiving
rAAVangiostatin compared to control HUVEC-2C cells. Western blot-
ting of the PEDF plasmid-transfected HUVEC-2C cells was used as
a positive control.
137creased extravascular albumin in the retinal parenchyma was
seen in the eyes of diabetic animals receiving rAAV-lacZ (Fig-
ure 2B). In the diabetic animals receiving rAAV- angiostatin,
however, albumin staining was observed only inside blood
vessels (Figure 2C).
To confirm the effect of rAAV-angiostatin on vascular per-
meability, we examined animals injected with intravenous
FITC-BSA 5, 10, and 15 days after induction of diabetes. Fig-
ure 3 shows representative micrographs of the eyes of normal
control and STZ-induced diabetic rats. FITC-BSA fluorescence
is limited to the vasculature in the normal retina (Figure 3B)
and diffusely increased throughout the retinal parenchyma at
5 days after STZ-induced diabetes in eyes receiving rAAV-
lacZ injection (Figure 3C). Increased fluorescence intensity
throughout the retinal parenchyma is still present at 10 (Fig-
ure 3D) and 15 (Figure 3E) days after STZ-induced diabetes
in eyes receiving rAAV-lacZ injection. Little fluorescence was
present in the retinal parenchyma in eyes receiving rAAV-
angiostatin injection (Figure 3F) at 5 days after induction of
diabetes. Retinal parenchyma fluorescence at 10 (Figure 3G)
and 15 (Figure 3H) days after induction of diabetes in eyes
with rAAV-angiostatin injection was decreased as compared
with eyes that received the rAAV-lacZ injection.
The retinal FITC-BSA fluorescence intensity was calcu-
lated and normalized to plasma fluorescence intensity by im-
age analysis of serial sections (Figure 4). Four SD rats were
represented by the number of sections to be examined at each
timepoint. The mean retinal FITC-BSA fluorescence inten-
sity in eyes receiving rAAV-angiostatin injection was
2.99±0.62 pixels at 5 days, 3.42±0.38 pixels at 10 days, and
3.30±0.40 pixels at 15 days after induction of diabetes. The
retinal FITC-BSA fluorescence intensity in eyes receiving
rAAV-lacZ injection was 3.59±0.31 pixels at 5 days, 3.77±0.51
pixels at 10 days, and 3.71±0.47 pixels at 15 days after induc-
tion of diabetes. Quantitative analysis showed that the fluo-
rescence was decreased in eyes receiving rAAV-angiostatin
as compared to eyes receiving rAAV-lacZ at 5 days (t=3.67,
n=49, p=0.001), 10 days (t=3.94, n=51, p<0.001), and 15 days
(t=3.52, n=56, p=0.001) after induction of diabetes.
rAAV-angiostatin influence on occludin loss:  Rats receiv-
ing rAAV-angiostatin in their right eyes and rAAV-lacZ in their
left eyes were sacrificed, and their eyes were enucleated for
western blotting analysis at 1, 5, 10, and 15 days after induc-
tion of diabetes. The retinal occludin content in normal con-
trol eye was 42.35±2.67 pixels. No differences in retinal
occludin content were detected between eyes receiving rAAV-
lacZ and rAAV-angiostatin injection at 1 (rAAV-lacZ:
45.82±3.08 pixels, rAAV-angiostatin: 43.62±2.78) and 5 days
(rAAV-lacZ: 38.96±2.22 pixels, rAAV-angiostatin: 40.65±3.46
pixels) after induction of diabetes. Ten days after diabetes in-
duction, retinal occludin content in eyes that received rAAV-
lacZ was 11.35±3.57 pixels and 34.73±3.17 pixels in eyes that
received rAAV-angiostatin occludin, a statistically significant
reduction (n=5, p=0.041, Figure 5). The retinal occludin con-
tent in rAAV-lacZ-treted eyes was higher (26.32±3.46 pixels)
at 15 days after induction of diabetes than it was at 10 days,
and there was no difference in rAAV-angiostatin-treated ani-
mals (29.21±2.94 pixels).
rAAV-angiostatin influence on VEGF expression:  One
day after diabetes induction, we observed rAAV-angiostatin-
mediated influence of retinal VEGF expression. The retinal
VEGF expression in normal control SD rat was 7.56±1.25 pix-
els. Retinal VEGF was 13.7±3.78 pixels (n=6) in rAAV-lacZ-
treated eyes and decreased to 8.69±3.23 pixels (n=6) in rAAV-
angiostatin-treated eyes (Figure 6, p=0.043). The retinal VEGF
expression in eyes receiving rAAV-lacZ was 11.45±2.73 pix-
els at 5 days, 9.12±3.12 pixels at 10 days, and 10.41±3.36
pixels at 15 days after induction of diabetes. The retinal VEGF
expression in rAAV-angiostatin-treated eyes was 9.52±3.96
pixels at 5 days, 8.31±2.67 pixels at 10 days, and 10.16±3.36
pixels at 15 days after induction of diabetes. There was no
statistical difference in retinal VEGF expression in rAAV-lacZ-
and rAAV-angiostatin-treated eyes at 5, 10, and 15 days after
induction of diabetes.
PEDF expression:  There was no significant difference
in retinal PEDF expression between eyes exposed to rAAV-
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Figure 8. The effect of rAAV-angiostatin gene transfer on retinal phos-
phorylation of p42/p44 MAP kinases at 1 day after STZ-based in-
duction of diabetes.  A: Representative blots show retinal phospho-
p42/44 MAP kinase and total p42/44 MAP kinase in normal control
eyes and in eyes injected with rAAV-lacZ or rAAV-angiostatin. B:
Retinal levels of phosphor-p42/p44 MAP kinase one day after STZ-
based induction of diabetes was reduced by rAAV-angiostatin (the
asterisk indicates significance using the Wilcoxon signed rank test,
n=5, p=0.043).
138angiostatin and rAAV-lacZ at 1, 5, 10, or 15 days after STZ
injection (Figure 7A). To further evaluate if rAAV-angiostatin
could influence PEDF expression, we infected HUVEC-2C
cells with rAAV-angiostatin. No PEDF expression was detected
in rAAV-angiostatin-infected HUVEC-2C cells (Figure 7B).
Western blot analysis of PEDF plasmid-transfected HUVEC-
2C cells was used as a positive control.
rAAV-angiostatin-mediated downregulation of phospho-
p42/p44 MAP kinase:  The retinal phosphor-p42/p44 MAP
kinase level of normal control SD rat was 7.03±1.22 pixels.
At one day after STZ injection, retinal phosphor-p42/p44 MAP
kinase levels were 7.43±0.93 pixels (n=5) in eyes receiving
rAAV-lacZ, and was decreased to 4.58±1.36 pixels(n=5) in
eyes receiving rAAV-angiostatin (Figure 8, p=0.043). No ef-
fect was observed at 5 days after STZ injection (5.64±1.28
pixels for eyes receiving rAAV-lacZ, and 5.44±1.65 pixels for
eyes receiving rAAV-angiostatin), 10 days (5.13±0.92 pixels
for eyes receiving rAAV-lacZ, and 5.97±1.87 pixels for eyes
receiving rAAV-angiostatin) and 15 days (7.37±1.33 pixels
for eyes receiving rAAV-lacZ, and 7.25±2.65 pixels for eyes
receiving rAAV-angiostatin)
DISCUSSION
 Retinal vascular leakage is a major cause of macular edema
in diabetic retinopathy and other retinal diseases [1-6]. Tradi-
tionally, laser photocoagulation has been used to reduce the
vascular leakage induced by diabetes [32,33]. Recently, anti-
inflammatory drugs such as triamcinolone [34], or pars-plana
vitrectomy with or without internal limiting membrane peel-
ing [35] have been used to attenuate the diabetic macular
edema. Due to the duration and severity, an ideal strategy would
be to develop an approach involving a single administration
of a vector that would result in long-term expression of a suit-
able therapeutic gene [36].
rAAV vectors are highly efficient gene delivery systems
which can facilitate long-term transduction [22,23]. We have
previously reported in several animal models a gene transfer
technique based on the use of rAAV vectors [8,23,25,26,37,38].
This gene transfer technique is particularly attractive for treat-
ing ocular disease for reasons of accessibility and long term
transduction, and potentially because it would enable clini-
cians to avoid repeated intravitreal injection [8,37]. We previ-
ously reported suppression of laser-induced choroidal
neovascularization by an rAAV vector expressing angiostatin
[8]. Here, we report that vascular leakage in experimental dia-
betic rats can be reduced by angiostatin delivery via an rAAV
vector. These results suggest that rAAV-angiostatin could be
beneficial in the treatment of diabetic macular edema.
Angiostatin is a proteolytic fragment of plasminogen and
contains kringle domains 1 through 4 [10]. It has been deter-
mined that angiostatin is a potent anti-angiogenic factor [11]
that can inhibit endothelial cell migration and induce apoptosis
in these cells [12]. Recently, intravitreal injection of angiostatin
was found to reduce vascular leakage in a rat model of experi-
mental diabetes and in oxygen induced retinopathy [9]. In the
same report, the expression of VEGF was found to be
downregulated by angiostatin.
VEGF is a potent angiogenic factor, expression of which
is increased in eyes with diabetic retinopathy [13,14]. VEGF,
which is also known as vascular permeability factor (VPF)
[39], increases microvascular permeability at very low con-
centrations [39], and may be important in the pathogenesis of
vascular leakage induced by diabetes [40]. Angiostatin-induced
reduction of vascular leakage occurs through blockade of
VEGF expression [15]. In our study, retinal VEGF expression
decreased in eyes receiving rAAV-angiostatin as compared to
rAAV-lacZ treated eyes at one and five days after induction of
diabetes. Vascular leakage was also decreased in eyes receiv-
ing intravitreal injection of rAAV-angiostatin compared to the
contralateral eyes receiving rAAV-lacZ injection at 5, 10, and
15 days after induction of diabetes.These results are consis-
tent with previous reports that angiostatin reduces the vascu-
lar leakage via blockade of VEGF [13-15,39,40]. How
angiostatin reduces vascular leakage through inhibition of
VEGF production is still under investigation.
It is known that p42/p44 MAP kinase phosphorylation is
induced by hypoxia [41]. This phosphorylation is diminished
by angiostatin in microvascular endothelial cells [42]. Phos-
phorylation of p42/p44 MAP kinase promotes VEGF expres-
sion by activating its transcription via recruitment of the AP-
2/Sp1 (activator protein-2) complex of the VEGF promoter
[43]. It is therefore plausible that inhibition of phosphoryla-
tion of p42/p44 MAP kinase by angiostatin suppresses VEGF
expression under conditions of hypoxia. In our study, retinal
phosphorylation of p42/p44 MAP kinase decreased in eyes
receiving rAAV-angiostatin at one day after induction of dia-
betes (Figure 8). Our results in STZ-induced diabetic rats sug-
gest that angiostatin suppresses VEGF expression by inhibi-
tion of phosphorylation of the p42/p44 MAP kinase.
BRB breakdown is a hallmark of vascular leakage in dia-
betic retinopathy and other retinal vascular diseases [44,45].
The tight junctions between the retinal vascular endothelial
cells constitute an essential structured component of BRB [18].
This barrier limits diffusion of molecules from vessel lumen
to the tissue, and thereby maintains the microenvironment of
the retina [46]. The barrier protein occludin is decreased in
experimental diabetes [21]. VEGF stimulates phosphorylation
and redistribution of occludin [19], which is subsequently
endocytosed and degraded [47,48]. This process is closely
related to the elevated vascular permeability in experimental
diabetes [18]. In our study, retinal occludin content in STZ-
induced diabetic rats was preserved in eyes receiving rAAV-
angiostatin as compared to eyes receiving rAAV-lacZ. The
rAAV-angiostatin-induced inhibition of VEGF may therefore
suppress vascular leakage by preserving retinal occludin con-
tent in STZ-induced diabetic rats
PEDF is a potent angiogenic inhibitor that is counter bal-
anced by the angiogenic effect of VEGF [49-51]. Decreased
expression of PEDF in retina is associated with ischemia-in-
duced retinal neovascularization and proliferative diabetic re-
tinopathy [50]. Recently, another proteolytic fragment of plas-
minogen-kringle 5 (K5) was noted to upregulate PEDF ex-
pression in a dose-dependent manner in vascular endothelial
cells and in the retina [15]. In our study, there was no statisti-
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receiving rAAV-angiostatin and the contralateral eyes receiv-
ing rAAV-lacZ. Our results also revealed that rAAV-angiostatin
did not upregulate PEDF expression in HUVEC-2C cells.
However, PEDF expression has been shown to be induced at
both the mRNA and protein level following injury in the eye
[52]. Further research is warranted to explore the effect of
rAAV-angiostatin on PEDF expression.
Our study showed that transgenic expression of rAAV-
angiostatin can reduce retinal vascular leakage in STZ-induced
diabetic rats. This effect is associated with downregulation of
retinal VEGF and phospho-p42/p44 MAP kinase expression,
and a reduction in the retinal occludin loss induced by diabe-
tes. However, the vascular leakage and VEGF expression af-
ter induction of diabetes in the SD rat model was demonstrated
to be a short-term effect [53]. Gene-based therapies can be as
effective and viable as real treatment if long-term expression
can be achieved. To demonstrate the long-term effect of rAAV-
angiostatin on vascular leakage induced by diabetes, an alter-
native animal model such as the Brown-Norway rat could be
used in a future study.
Diabetic macular edema is a major cause of vision loss in
diabetic patients [7]. On the basis of these findings, we be-
lieve that a similar vector and therapeutic gene could eventu-
ally be a useful strategy for long-term preventive or adjunc-
tive therapy for macular edema induced by diabetes. It could
serve as the basis for an alternative treatment for patients who
are suffering from diabetic macular edema as well as a poten-
tially preventive therapeutic modality for diabetic patients who
are at risk for development of macular edema.
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